{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:37:07Z","timestamp":1790159827507,"version":"4.1.0"},"reference-count":98,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["097377"],"award-info":[{"award-number":["097377"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency.<\/jats:p>","DOI":"10.3390\/jof2020015","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T12:13:20Z","timestamp":1464264800000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Aspergillosis in Chronic Granulomatous Disease"],"prefix":"10.3390","volume":"2","author":[{"given":"Jill","family":"King","sequence":"first","affiliation":[{"name":"Aberdeen Fungal Group, MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Henriet","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Amalia Children\u2019s Hospital, Nijmegen 6500 HB, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"Aberdeen Fungal Group, MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/INF.0b013e3181f13b23","article-title":"Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: A multicenter study in France","volume":"30","author":"Obenga","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/cir731","article-title":"Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey","volume":"53","author":"Blumental","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/cid\/ciu1154","article-title":"Common severe infections in chronic granulomatous disease","volume":"60","author":"Marciano","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bcmd.2010.07.012","article-title":"Hematologically important mutations: X-linked chronic granulomatous disease (third update)","volume":"45","author":"Roos","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cei.12202","article-title":"Molecular diagnosis of chronic granulomatous disease","volume":"175","author":"Roos","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1651-2227.1995.tb13575.x","article-title":"Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden","volume":"84","author":"Ahlin","year":"1995","journal-title":"Acta Paediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: Chronic granulomatous disease in the United Kingdom and Ireland: A comprehensive national patient-based registry","volume":"152","author":"Jones","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2008.06.012","article-title":"Chronic granulomatous disease in Israel: Clinical, functional and molecular studies of 38 patients","volume":"129","author":"Wolach","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s10875-011-9567-x","article-title":"Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease","volume":"31","author":"Fattahi","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.freeradbiomed.2012.04.022","article-title":"Regulation of innate immunity by NADPH oxidase","volume":"53","author":"Segal","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","article-title":"Residual NADPH oxidase and survival in chronic granulomatous disease","volume":"363","author":"Kuhns","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4614-4726-9_3","article-title":"Invasive fungal infections in patients with chronic granulomatous disease","volume":"764","author":"Henriet","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/infdis\/jis473","article-title":"Aspergillus nidulans and chronic granulomatous disease: A unique host-pathogen interaction","volume":"206","author":"Henriet","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/j.1439-0507.2010.02001.x","article-title":"Osteomyelitis due to Aspergillus species in chronic granulomatous disease: An update of the literature","volume":"54","author":"Dotis","year":"2011","journal-title":"Mycoses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12281-013-0168-4","article-title":"Invasive fungal infections in the child with chronic granulomatous disease","volume":"8","author":"Warris","year":"2014","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-3476(05)82023-2","article-title":"Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease","volume":"125","author":"Mouy","year":"1994","journal-title":"J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa021931","article-title":"Itraconazole to prevent fungal infections in chronic granulomatous disease","volume":"348","author":"Gallin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e3182195808","article-title":"A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease","volume":"30","author":"Welzen","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Van den Berg, J.M., van Koppen, E., Ahlin, A., Belohradsky, B.H., Bernatowska, E., Corbeel, L., Espanol, T., Fischer, A., Kurenko-Deptuch, M., and Mouy, R. (2009). Chronic granulomatous disease: The European experience. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005234"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00431-008-0680-7","article-title":"Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan","volume":"167","author":"Kobayashi","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1157\/13106774","article-title":"Chronic granulomatous disease in pediatric patients: 25 years of experience","volume":"35","author":"Margareto","year":"2007","journal-title":"Allergol. Immunopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJM200212263472618","article-title":"Multidrug resistance in Aspergillus fumigatus","volume":"347","author":"Warris","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJM200309183491220","article-title":"Preventing fungal infections in chronic granulomatous disease","volume":"349","author":"Verweij","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"The International Chronic Granulomatous Disease Cooperative Study Group (1991). A controlled trial of interferon \u03b3 to prevent infection in chronic granulomatous disease. N. Engl. J. Med., 324, 509\u2013516.","DOI":"10.1056\/NEJM199102213240801"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S0090-1229(05)80044-3","article-title":"Interferon-\u03b3 in the treatment of the chronic granulomatous diseases of childhood","volume":"61","author":"Gallin","year":"1991","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_27","first-page":"295","article-title":"Recombinant human interferon-\u03b3 in patients with chronic granulomatous disease\u2013European follow up study","volume":"154","author":"Weening","year":"1995","journal-title":"Eur. J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1183\/09031936.00118414","article-title":"Pulmonary manifestations in adult patients with chronic granulomatous disease","volume":"45","author":"Salvator","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-199809000-00004","article-title":"Aspergillus nidulans infection in chronic granulomatous disease","volume":"77","author":"Segal","year":"1998","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1080\/13693780902736620","article-title":"Invasive aspergillosis in chronic granulomatous disease","volume":"47","author":"Segal","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jinf.2013.12.008","article-title":"Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome","volume":"68","author":"Gamaletsou","year":"2014","journal-title":"J. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijid.2003.06.001","article-title":"Osteomyelitis due to aspergillus spp. In patients with chronic granulomatous disease: Comparison of Aspergillus nidulans and Aspergillus fumigatus","volume":"8","author":"Dotis","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/527446","article-title":"Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood","volume":"46","author":"Galluzzo","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/INF.0000000000000840","article-title":"Chronic granulomatous disease: A large, single-center US experience","volume":"34","author":"Bortoletto","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pbc.20426","article-title":"Chronic granulomatous disease presenting with disseminated intracranial aspergillosis","volume":"47","author":"Alsultan","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00381-009-1003-7","article-title":"Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located aspergillus abscess mimicking intracranial tumor","volume":"26","author":"Patiroglu","year":"2010","journal-title":"Child\u2019s Nerv. Syst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1651-2227.1996.tb14143.x","article-title":"Aspergillus endocarditis in chronic granulomatous disease","volume":"85","author":"Casson","year":"1996","journal-title":"Acta Paediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/j.1439-0507.2009.01835.x","article-title":"Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease","volume":"54","author":"Mortensen","year":"2011","journal-title":"Mycoses"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00247-003-0919-4","article-title":"The radiological spectrum of invasive aspergillosis in children: A 10-year review","volume":"33","author":"Thomas","year":"2003","journal-title":"Pediatr. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1148\/rg.255055011","article-title":"Imaging of chronic granulomatous disease in children","volume":"25","author":"Khanna","year":"2005","journal-title":"Radiographics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(05)70238-3","article-title":"Laboratory diagnosis of invasive aspergillosis","volume":"5","author":"Hope","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1439-0507.2002.00797.x","article-title":"Aspergillus nidulans is frequently resistant to amphotericin b","volume":"45","author":"Kontoyiannis","year":"2002","journal-title":"Mycoses"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1404.071157","article-title":"Emericella quadrilineata as cause of invasive aspergillosis","volume":"14","author":"Verwei","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/13693786.2010.499916","article-title":"Aspergillus species intrinsically resistant to antifungal agents","volume":"49","author":"Warris","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/JCM.01509-12","article-title":"Aspergillus tanneri sp. Nov., a new pathogen that causes invasive disease refractory to antifungal therapy","volume":"50","author":"Sugui","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/599345","article-title":"Invasive aspergillosis due to Neosartorya udagawae","volume":"49","author":"Vinh","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"12","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/422009","article-title":"Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance","volume":"190","author":"Marr","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zou, M., Tang, L., Zhao, S., Zhao, Z., Chen, L., Chen, P., Huang, Z., Li, J., and Fan, X. (2012). Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043347"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1164\/ajrccm.157.5.9709068","article-title":"Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease","volume":"157","author":"Verweij","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-015-0905-x","article-title":"Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients","volume":"19","author":"Eigl","year":"2015","journal-title":"Crit. Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10096-003-1007-2","article-title":"Pulmonary aspergillosis in a patient with chronic granulomatous disease: Confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole","volume":"22","author":"Sambatakou","year":"2003","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/JCM.03216-14","article-title":"Validation of a new aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid","volume":"53","author":"Chong","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole vs. amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","author":"Mikulska","year":"2012","journal-title":"J. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jaad.2013.09.051","article-title":"Recurrent erythematous plaques on sun-exposed sites in an African American boy with chronic granulomatous disease","volume":"70","author":"Turegano","year":"2014","journal-title":"Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archdermatol.2009.362","article-title":"Melanoma associated with long-term voriconazole therapy: A new manifestation of chronic photosensitivity","volume":"146","author":"Miller","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1086\/430068","article-title":"Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection","volume":"40","author":"Segal","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: A multicentre survey","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_66","first-page":"976","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"Bernardo","year":"2013","journal-title":"Ann. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mmy\/myv087","article-title":"Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Heinz","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/INF.0000000000000963","article-title":"Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area","volume":"35","author":"Vanstraelen","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"Arendrup","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist. Update"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/162.2.523","article-title":"Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae","volume":"162","author":"Rex","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1774-9987.2005.00227.x","article-title":"Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis","volume":"9","author":"Dogu","year":"2005","journal-title":"Ther. Apher. Dial."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1537-2995.2010.02993.x","article-title":"The relationship between alloimmunization and postransfusion granylocyte survivial: Experience in a chronic granulomatous disease cohort","volume":"51","author":"Heim","year":"2011","journal-title":"Transfusion"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1537-2995.1996.36111297091747.x","article-title":"Alloimmunization after granulocyte transfusions","volume":"36","author":"Stroncek","year":"1996","journal-title":"Transfusion"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1537-2995.1993.33293158050.x","article-title":"Prolonged neutropenia resulting from antibodies to neutrophil-specific antigen NB1 following marrow transplantation","volume":"33","author":"Stroncek","year":"1993","journal-title":"Transfusion"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.12-S2-7","article-title":"Role of macrophages in host defense against aspergillosis and strategies for immune augmentation","volume":"12","author":"Segal","year":"2007","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood.V95.11.3548","article-title":"Interferon-\u03b3 improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation","volume":"95","author":"Newburger","year":"2000","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V98.2.436","article-title":"Improved superoxide-generating ability by interferon \u03b3 due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene","volume":"98","author":"Ishibashi","year":"2001","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM198807213190305","article-title":"Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon \u03b3","volume":"319","author":"Ezekowitz","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI113153","article-title":"Recombinant interferon \u03b3 augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease","volume":"80","author":"Ezekowitz","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1073\/pnas.85.13.4874","article-title":"Recombinant human interferon-\u03b3 reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood","volume":"85","author":"Sechler","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2249.1992.tb03062.x","article-title":"Treatment of patients with chronic granulomatous disease with recombinant human interferon-\u03b3 does not improve neutrophil oxidative metabolism, cytochrome B558 content or levels of four anti-microbial proteins","volume":"88","author":"Muhlebach","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V79.6.1558.1558","article-title":"Prolonged recombinant interferon-\u03b3 therapy in chronic granulomatous disease: Evidence against enhanced neutrophil oxidase activity","volume":"79","author":"Woodman","year":"1992","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/infdis\/jit103","article-title":"Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease","volume":"207","author":"Henriet","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MEG.0b013e328277ef5f","article-title":"Efficiency of hydroxychloroquine in the treatment of granulomatous complications in chronic granulomatous disease","volume":"20","author":"Arlet","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_88","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology"},{"key":"ref_89","first-page":"95","article-title":"Anakinra for the inflammatory complications of chronic granulomatous disease","volume":"69","author":"Netea","year":"2011","journal-title":"Neth. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/ajg.2015.135","article-title":"Treatment with Anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis","volume":"110","author":"Hahn","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1073\/pnas.1322831111","article-title":"IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans","volume":"111","author":"Smeekens","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2015-05-644773","article-title":"NADPH oxidase controls neutrophilic response to sterile inflammation in mice by regulating the IL-1alfa\/G-CSF axis","volume":"126","author":"Bagaitkar","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Gresnigt, M.S., Bozza, S., Becker, K.L., Joosten, L.A.B., Abdollahi-Roodsaz, S., van der Berg, W.B., Dinarello, C.A., Netea, M.G., Fontaine, T., and de Luca, A. (2014). A Polysaccharide Virulence factor from Aspergillus fumigatus elicits antiinflammatory effects through induction of interleukin-1 receptor antagonist. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003936"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Teira","year":"2014","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/QCO.0b013e328358b0a4","article-title":"Invasive fungal infection in chronic granulomatous disease: Insights into pathogenesis and management","volume":"25","author":"Falcone","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","article-title":"Clinical outcome in children with chronic granulomatous disease managed conservatively or with haematopoietic stem cell transplant","volume":"132","author":"Cole","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/1566523214666140918113201","article-title":"Gene therapy for chronic granulomatous disease: Current status and future perspectives","volume":"14","author":"Kaufmann","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.gene.2013.03.098","article-title":"Gene therapy for PIDs: Progress, pitfalls and prospects","volume":"525","author":"Mukherjee","year":"2013","journal-title":"Gene"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/2\/2\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:24:32Z","timestamp":1760210672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/2\/2\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":98,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["jof2020015"],"URL":"https:\/\/doi.org\/10.3390\/jof2020015","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}